Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $101

Author: Benzinga Newsdesk | April 15, 2024 02:19pm
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $95 to $101.

Posted In: EW

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist